Yao advised GIs to consider GLP-1 patients to be at risk for poor quality of bowel preparation
Whether and when the FDA acts on a regulatory submission depends on Eli Lilly's filing timeline and Phase 3 results, neither of which is fixed as of this writing
In their statement, the FDA said they have confirmed with the drugs manufacturer (Eli Lilly and Company) that, their stated product availability and manufacturing capacity can meet the present and projected national demand. Tirzepatide is the active ingredient in the GLP-1 drug Mounjaro
Research has consistently demonstrated semaglutides impressive results
Patients who stop the medication gain back on average two thirds of the weight they had lost
AMPK, a key regulator of cellular energy balance (106), activation, lipogenic transcription factor suppression (107), and intestinal cholesterol absorption inhibition (108), is one of the mechanisms by which TSS has been shown to have anti-inflammatory, antioxidant, cholesterol-lowering, and anti-carcinogenic effects (109113)
